Post-Contrast AKI Risk in a Patient with Marginal Renal Function
A 71-year-old man with type 2 diabetes and known coronary artery disease presents to the ED with 6 hours of substernal chest pressure and a troponin that rose from 0.04 to 0.9 ng/mL. The ED team requests a CT coronary angiogram with contrast. His eGFR measured 3 weeks ago was 42 mL/min/1.73 m², and his most recent creatinine is 1.7 mg/dL. He takes metformin, lisinopril, and furosemide. Blood pressure is 102/64 mmHg, and he is mildly volume depleted after poor oral intake. The requesting team states the study is needed to exclude left main disease before a possible catheterization. No prior contrast has been given in the past 6 months.
1. Estimate this patient's risk of contrast-associated acute kidney injury and identify the modifiable factors you would address before scanning.
Read the worked answer
Risk is elevated but not prohibitive. eGFR 42 mL/min/1.73 m² is moderate CKD; the 2020 ACR/NKF consensus flags eGFR <30 as the threshold where contrast should generally be avoided or strictly justified, and 30–44 as a group with increased risk but acceptable benefit when the indication is strong. The pre-catheterization question (left main disease) is a reasonable indication.
Modifiable factors:
- Volume: BP 102/64 with poor intake suggests hypovolemia. Volume expansion with isotonic saline (e.g., 1 mL/kg/h starting 1 h before and continuing 3–6 h after, capped by cardiac status) is the intervention with the best evidence.
- Neprotoxic drugs: Hold metformin per institutional protocol (typically 48 h post-contrast in at-risk patients), and consider holding furosemide and lisinopril around the study after discussion with the primary team; diuretics worsen volume depletion.
- Contrast volume: Use the lowest diagnostic volume and iso-/low-osmolar agent; avoid repeat contrast within 48–72 h.
Do not withhold a strongly indicated study solely because of eGFR 42; document the risk-benefit discussion and arrange a follow-up creatinine in 48–72 h.
2. The CT technologist asks whether a non-contrast calcium score alone would answer the clinical question. How do you respond, and what alternative would you offer if contrast were deemed unacceptable?
Read the worked answer
A calcium score cannot exclude left main disease. It quantifies calcified plaque, but non-calcified (soft) plaque and stenosis severity are not assessed; a zero score has high negative predictive value for any coronary calcium but does not reliably exclude non-calcified plaque in a symptomatic patient with a rising troponin. It would not answer the pre-catheterization question.
Alternatives if contrast were truly contraindicated:
- Invasive coronary angiography - the definitive test, but itself uses iodinated contrast.
- Stress testing (stress echo, stress MRI, or SPECT/PET perfusion) - assesses ischemia rather than anatomy and may be appropriate if the question shifts from anatomy to physiology.
- MR coronary angiography - limited spatial resolution and availability; not standard for excluding left main disease.
Given the rising troponin and the specific left-main question, proceeding with a volume-optimized contrast-enhanced study after the mitigations above is the most defensible path; document the discussion.